{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG001","lowerLimit":"1.9","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"30"}],"units":"Participants"}],"description":"Duration of CHR will be computed from the first day all criteria are met for CHR, provided they are confirmed 4 weeks later, until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death. Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 2"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG002","title":"Cohort 3"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG003","title":"Cohort 3a"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG004","title":"Cohort 3b"}],"paramType":"MEDIAN","populationDescription":"All treated participants with CCyR","reportingStatus":"POSTED","timeFrame":"From first day criteria are met for CHR until date of disease progression or death (assessed up to September 2016, approximately 90 months)","title":"Duration of Complete Hemotologic Response (CHR)","type":"SECONDARY","unitOfMeasure":"months"}